ClinicalTrials.gg
Not yet recruitingNCT06913075ADYUpdated Nov 17, 2026

FET in Adenomyosis

An interventional study of GnRH agonist downregulation and GnRH agonist and Letrozole in Adenomyosis, sponsored by Indira IVF Hospital Pvt Ltd. Not yet recruiting at 1 site in India. Open to female participants aged 21 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Indira IVF Hospital Pvt Ltd · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
21 Years to 42 Years
Sex
Female
01

Study summary

Purpose of the Study:

To compare the effectiveness of GnRH agonist downregulation alone versus GnRH agonist combined with letrozole in improving pregnancy outcomes in women with adenomyosis undergoing frozen embryo transfer (FET).

Research Question:

Is the combined use of GnRH agonist and letrozole more effective than GnRH agonist downregulation alone in achieving better ongoing pregnancy rates in adenomyosis cases undergoing FET?

Hypothesis:

Null Hypothesis (H₀): The combined use of GnRH agonist and letrozole is not more effective than GnRH agonist downregulation alone in achieving a higher ongoing pregnancy rate in adenomyosis cases undergoing FET.

Study Outcomes:

Primary Outcome: Ongoing pregnancy rate at 12 weeks of gestation.

02

Conditions studied

  • Adenomyosis

Browse trials for

Keywords

  • Frozen embryo transfer
  • Adenomyosis
  • ongoing pregnancy rate
  • live birth rate
03

In context

Adenomyosis

142 studies on the registry are indexed under Adenomyosis; 54 are open to participants now.

This study's planned enrollment of 700 is above the median of 100 across 78 interventional studies indexed under Adenomyosis.

Browse Adenomyosis studies →

Lead sponsor

Indira IVF Hospital Pvt Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of adenomyosis confirmed via transvaginal ultrasound as per MUSA criteria History of infertility requiring frozen embryo transfer (FET). Availability of at least one good-quality frozen embryo for transfer

Exclusion criteria

Exclusion Criteria:

≥ 30 kg/m2 Presence of endocrine disorders; (uncontrolled diabetes mellitus, / hyperprolactinemia, thyroid dysfunction, Congenital adrenal hyperplasia, Cushing syndrome, or polycystic ovary syndrome Previous major uterine surgery Gestational carrier Fertility preservation

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Active comparator
    Group A

    Drug: GnRH agonist downregulation

  • Active comparator
    Group B

    Drug: GnRH agonist and Letrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Ongoing pregnancy rate

    Presence of gestational sacs with a heartbeat at the 12th gestational week. The ongoing pregnancy rate will be calculated using the below formula. Ongoing pregnancy rate: (the number of ongoing pregnancy cases/the number of clinical pregnancy cases) × 100%

    Time frame: 12 weeks of gestation

Secondary outcomes

  1. Implantation Rate

    The number of gestational sacs observed by transvaginal ultrasound at the 6th gestational week per the number of embryos transferred. The implantation rate will be calculated using the below formula. Implantation rate: (The number of gestational sacs observed/ number of embryos transferred) × 100

    Time frame: 4 weeks after embryo transfer

  2. Chemical Pregnancy rate

    Detection of a fetal heartbeat on transvaginal ultrasound at the 6th gestational week. The clinical pregnancy rate will be calculated using the below formula.

    Time frame: 4 weeks after embryo transfer

  3. Biochemical loss rate

    Pregnancies diagnosed only by β-human chorionic gonadotropin detection without a gestational sac visualized by vaginal ultrasound at the 6th gestational week. The biochemical loss rate will be calculated using the below formula. Biochemical loss rate: (the number of biochemical pregnancy loss cases/the number of women per group) × 100%

    Time frame: 4 weeks after embryo transfer

  4. 1st trimester loss

    First-trimester loss refers to the spontaneous loss of a pregnancy occurring before the end of the 12th week of gestation

    Time frame: 12 weeks of gestation

  5. 2nd trimester loss

    Second-trimester loss refers to the spontaneous loss of a pregnancy occurring between 13 and 20 weeks of gestation.

    Time frame: 20 weeks of gestation

  6. Live Birth Rate

    The number of deliveries that resulted in at least one live birth per 100 Embryo transferred cycle. Live birth rate: (The number of live births / the number of embryos transferred cycle) × 100

    Time frame: Post delivery after completion of 20 weeks of gestation

07

Study locations

1 site
  • Indira IVF Pvt Hospital
    Udaipur, Rajasthan 313001, India
    • Vipin Chandra, DGO · Contactdrvipinchandra@indiraivf.in
    • Taruna Jhamb, MD · Principal investigator
    • Peter Humaidan, DMSc · Sub investigator
    • Vipin Chandra, DGO · Sub investigator
    • Snehadarshani Karnath, MD · Sub investigator
    • Yasha Pandey, MD · Sub investigator
    • Akanksha Jangid, MD · Sub investigator
    • Pawan Yadav, MD · Sub investigator
    • Pooja Shinde, DNB · Sub investigator
    • Nisha Tiwari, DNB · Sub investigator
    • Tanu Batra, DNB · Sub investigator
    • Amol Lunkad, MD · Sub investigator
    • Rinoy Sreedharan, MD · Sub investigator
08

References and documents

Publications

  • Salim R, Riris S, Saab W, Abramov B, Khadum I, Serhal P. Adenomyosis reduces pregnancy rates in infertile women undergoing IVF. Reprod Biomed Online. 2012 Sep;25(3):273-7. doi: 10.1016/j.rbmo.2012.05.003. Epub 2012 May 23. PubMed 22832421 ↗
  • Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril. 2017 Sep;108(3):483-490.e3. doi: 10.1016/j.fertnstert.2017.06.025. PubMed 28865548 ↗
  • Han B, Liang T, Zhang W, Ma C, Qiao J. The effect of adenomyosis types on clinical outcomes of IVF embryo transfer after ultra-long GnRH agonist protocol. Reprod Biomed Online. 2023 Feb;46(2):346-351. doi: 10.1016/j.rbmo.2022.09.021. Epub 2022 Sep 26. PubMed 36549997 ↗
  • Sharma S, RoyChoudhury S, Bhattacharya MP, Hazra S, Majhi AK, Oswal KC, Chattopadhyay R. Low-dose letrozole - an effective option for women with symptomatic adenomyosis awaiting IVF: a pilot randomized controlled trial. Reprod Biomed Online. 2023 Jul;47(1):84-93. doi: 10.1016/j.rbmo.2023.03.010. Epub 2023 Mar 18. PubMed 37149412 ↗
  • Li Y, Ge L, Yang X, Cui L, Chen ZJ. Effects of duration of long-acting GnRH agonist downregulation on assisted reproductive technology outcomes in patients with adenomyosis: a retrospective cohort study. Front Med (Lausanne). 2023 Sep 26;10:1248274. doi: 10.3389/fmed.2023.1248274. eCollection 2023. PubMed 37822471 ↗

Individual participant data

Plan to share: Yes — he Individual Participant Data (IPD) will be shared with authorized researchers upon request. The supporting documents, including the study protocol, SAP, and ICF, will be provided alongside the IPD to ensure comprehensive understanding and proper data interpretation. When: IPD will be available after the completion of the study and publication of primary results. How: IPD will be shared through a secure data repository or via encrypted files sent through secure email upon request, following proper data use agreements.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After publication

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Sep 2027, 7 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Jun 2026 → Jan 2027, primary completion Jul 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2025
First posted
Apr 6, 2025
StartEst.
Jan 16, 2027was Jun 2026
Primary completionEst.
Sep 15, 2027was Jul 2026
CompletionEst.
Dec 23, 2027was Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 25, 2026→Jan 16, 2027
Nov 17, 2026
Primary completion
Jul 15, 2026→Sep 15, 2027
Nov 17, 2026
Study completion
Dec 23, 2026→Dec 23, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Jun 25, 2026→Jan 16, 2027
    Primary completion Jul 15, 2026→Sep 15, 2027
    Study completion Dec 23, 2026→Dec 23, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06913075
Lead sponsor
Indira IVF Hospital Pvt Ltd
Responsible party
Sponsor
First posted
Apr 6, 2025
Start date
Jan 16, 2027 (estimated)
Primary completion
Sep 15, 2027 (estimated)
Completion
Dec 23, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Taruna Jhamb, MD
Contact
centerhead.udaipur@indiraivf.in
+91 9799035674

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gonadotropin-releasing Hormone Analog · Letrozole

Start the discussion